Moossavi M, Bagheri B, Scher R K
Department of Dermatology, Columbia University College of Physicians and Surgeons, New York City, New York, USA.
Dermatol Clin. 2001 Jan;19(1):35-52. doi: 10.1016/s0733-8635(05)70228-x.
Systemic antifungal therapy for superficial mycoses has advanced greatly since the introduction of griseofulvin in 1958. The discovery of the azole antifungal compounds, ketoconazole, itraconazole, and fluconazole, allowed for a broader spectrum of treatment and a shorter treatment duration. Terbinafine, through a unique mechanism of action, has a fungicidal power not seen previously in the other antifungals. It is important to use our knowledge of the pharmacology in combination with clinical experience and cost of therapy in order to select the proper drug. The search to identify new oral antifungal agents should continue, since none of the five currently used drugs fulfill the criteria of the "ideal" antifungal.
自1958年灰黄霉素问世以来,用于治疗浅表真菌病的全身抗真菌疗法有了很大进展。唑类抗真菌化合物酮康唑、伊曲康唑和氟康唑的发现,使得治疗范围更广,治疗时间更短。特比萘芬通过独特的作用机制,具有以往其他抗真菌药物所没有的杀菌能力。结合药理学知识、临床经验和治疗成本来选择合适的药物很重要。鉴于目前使用的五种药物均不符合“理想”抗真菌药物的标准,因此寻找新型口服抗真菌药物的工作应继续进行。